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INTRODUCTION
Wiskott-Aldrich syndrome (WAS) is an X-linked prima-
ry immunodeficiency characterized by a clinical triad of im-
munodeficiency, thrombocytopenia, and eczema (1, 2). WAS
is caused by mutations in the gene encoding Wiskott-Aldrich
syndrome protein (WASP) that affect all hematopoietic stem
cells including lymphocytes, monocytes, neutrophils and pl-
atelets (3). Various WASP gene mutations have been reported
in patients with WAS and X-linked thrombocytopenia, a
clinically mild allelic variant (4-9). 
The treatment of WAS depends on the severity of the im-
munodeficiency. In severe cases of WAS, the immunodeficien-
cy limits the life expectancy of the patient, and immune re-
constitution is the treatment of choice. Imai et al. (10) demon-
strated correlations between the clinical phenotype, the extent
of the mutation, and the presence or absence of WASP and
also recommended hematopoietic stem cell transplantation
(HSCT) especially for the patients with WASP-negative WAS.
Recently, there have been reports of successful treatment of
WAS by unrelated HSCT with cord blood (CB) as well as
bone marrow transplant when a matched sibling donor was
unavailable (11-16). Although phenotypic corrections for
immunologic and hematologic parameters have been report-
ed, genotypic corrections for WAS with cord blood stem cell
transplantation (CBSCT) have not been demonstrated. 
In this report, we demonstrate 2 cases of WAS which were
phenotypically and genotypically corrected with unrelated
CBSCT.
CASE REPORT 
Patient 1 (UPN 1) is a male who was diagnosed with WAS
at the age of 5 months. He presented with incidentally detect-
ed thrombocytopenia (23,000/μ L) with skin eczema and se-
vere, recurrent otitis media and diarrhea on admission. The
second male patient (UPN 2) presented with neonatal throm-
bocytopenia at birth and received intermittent intravenous
immunoglobulin (IVIG). Thereafter he experienced skin ec-
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Phenotypic and Genotypic Correction of WASP Gene Mutation in
Wiskott-Aldrich Syndrome by Unrelated Cord Blood Stem Cell 
Transplantation
We present two cases of Wiskott-Aldrich syndrome (WAS), in which nonsense mu-
tations in the WASP gene were corrected phenotypically as well as genotypically
by unrelated cord blood stem cell transplantation (CBSCT). Two male patients were
diagnosed with WAS at the age of 5-month and 3-month and each received unre-
lated CBSCT at 16-month and 20-month of age, respectively. The infused cord blo-
od (CB) units had 4/6 and 5/6 HLA matches and the infusion doses of total nuclea-
ted cells (TNC) and CD34+ cells were 6.24×10
7/kg and 5.08×10
7/kg for TNC and
1.33×10
5/kg and 4.8×10
5/kg for CD34+ cells, for UPN1 and UPN2, respectively.
Complete donor cell chimerism was documented by variable number tandem re-
peat (VNTR) with neutrophil engraftment on days 31 and 13 and platelets on days
58 and 50, respectively. Immunologic reconstitution demonstrated that CBSCT re-
sulted in consistent and stable T-, B-, and NK-cell development. Flow cytometric
analysis for immunologic markers and sequence analysis of the WASP gene mu-
tation revealed a normal pattern after CBSCT. These cases demonstrate that CBs
can be an important source of stem cells for the phenotypical and genotypical cor-
rection of genetic diseases such as WAS.
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nia, until he visited our hospital at 3 months old. Flow cyto-
metric analysis of peripheral blood mononuclear cells (PBMC)
for these 2 patients revealed a defect in WASP, leading to the
diagnosis of WAS. Subsequently, the nonsense mutations,
Arg211stop and Arg13stop, were confirmed by genomic ana-
lysis (17). Before transplantation, these patients were treated
with monthly infusions of IVIG as well as supportive treat-
ment but there was no clinical improvement.
CBSCT was performed in a laminar air flow room with con-
ventional supportive therapy. The pre-transplantation con-
ditioning regimen for the 2 patients was 1 mg/kg of busul-
fan intravenously every 6 hr on days -9 through -6. This was
followed by 50 mg/kg of intravenous cyclophosphamide on
days -5 through -3 and 30 mg/kg of intravenous antithymo-
cyte globulin (ATG) on days -3 through -1. Prophylaxis for
acute graft versus host disease (GVHD) included continuous
infusion of cyclosporine A beginning on day -1, targeting
whole blood levels to be 200 to 400 ng/mL, and 1 mg/kg/dose
of methylprednisone every 12 hr on days 5 through 19, and
then a taper. 
The degree of human leukocyte antigen (HLA) match con-
firmed by high resolution DNA typing between the infused
CB and the patients was 4/6 for UPN 1 and 5/6 for UPN 2.
Infused cell doses of TNC and CD34+ cells for UPN1 and
UPN2 were 6.24×107/kg and 5.08×107/kg for TNC, res-
pectively, and 1.33×105/kg and 4.8×105/kg for CD34+
cells, respectively. 
T-, NK-, and B-cell enumeration and quantitative immu-
noglobulin studies (for immunoglobulin [Ig] G, A, M, D,
and E) were performed. Cytofluorographic analyses of lym-
phocyte subpopulations were performed with murine mon-
oclonal antibodies conjugated to either fluorescein (FITC)
or phycoerythrin (PE) and then analyzed by flow cytometry
(FACScan; Becton Dickinson, San Jose, CA, U.S.A.). 
Heparinized venous blood samples from patients and fam-
ily members were fractionated on a Ficoll-Hypaque gradient
to isolate PBMCs. For mutational analysis, genomic DNA
was extracted from the peripheral lymphocytes, and 12 WASP
gene exons were amplified by polymerase chain reaction (PCR)
followed by direct sequencing according to the protocol of
Sasahara et al. (18). 
Hematopoietic reconstitution following CBSCT was un-
eventful, with an absolute neutrophil count (ANC) of more
than 500/μ L on days 31 and 13 and a platelet count of more
than 20,000/μ L on days 58 and 50, for UPN 1 and UPN 2,
respectively. Molecular chimerism studies using the VNTR
method showed a complete donor cell type for these patients
(data not shown). Acute GVHD did not occur, even after the
infusion of HLA 1 or 2 antigen mismatched CB. UPN 1 expe-
rienced 1 episode of sepsis with B. cepacia during the pre-en-
graftment period without any complications. UPN 2 expe-
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WAS, Wiskott-Aldrich Syndrome; HLA, human leukocyte antigen; TNC,
total nucleated cells; ANC, absolute neutrophil count.
UPN 1 UPN 2
Age at transplantation (month) 16 20
Degree of HLA mismatch 2 1 
Preparative regimen Bu, Cy, ATG Bu, Cy, ATG
Infused cell dose
TNC (10
7/kg) 6.24 5.08
CD34+ cell (10
5/kg) 1.33 4.8
Time to engraftment (day)
ANC (>500/μ L) 31 13
Platelet (>20,000/μ L) 58 50
Follow-up duration (month) 60 55
Table 1. Cord blood stem cell transplantation data in children with
WAS
WAS, Wiskott-Aldrich Syndrome; NA, not available; mo, months.
UPN 1
Post-transplant
Pre-transplant Pre-transplant
Post-transplant
7 mo  16 mo  48 mo 60 mo 7 mo  12 mo  24 mo  55 mo
UPN 2
Total eosinophil (μ /L) 800 200 288 360 160 1,600 300 90 110 100
IgE (IU/mL) 786 44.4 25.7 134.9 66.1 1,713 216 84.77 84.77 41.9
IgG (mg/dL) 1,912 NA 589 1,010 1,030 NA NA NA NA 1,087
IgA (mg/dL) 72.3 NA 29.2 104 105 NA NA NA NA 172
IgM (mg/dL) 30.4 NA 270 254 246 NA NA NA NA 198
IgD (mg/dL) 0.397 NA 70 81 NA NA NA NA 58.3
Lymphocyte subset
T3 (CD3) (%) 47 NA 60.6 58 64 36 NA 43.3 62.6 70.1
T4 (CD4) (%) 30 NA 35.8 29 29 31 NA 29.3 33 43.9
T8 (CD8) (%) 7 NA 26 28 32 5 NA 13.1 22.3 23.9
T4/T8 ratio 5.7:1 NA 1.38:1 1.04:1 0.91:1 6.2:1 NA 2.2:1 1.5:1 1.8:1
B (CD19) (%) 32 NA 33.9 19 26 32 NA 49.7 25 23.2
NK (CD16/56) (%) 18 NA 6.19 19 9 31 NA 13.8 12.1 5.9
Table 2. Immunological laboratory data of pre-/post-transplantation in children with WASrienced fever and respiratory distress with hypoxemia due to
pulmonary edema as well as skin rashes on the trunk in the
pre-engraftment period (from days 8 to days 10), which mim-
ics engraftment syndrome. He recovered with oxygen supply
via endotracheal tube and fluid restriction as well as methyl-
prednisone therapy. Both patients were clinically well with-
out eczematous skin and recurrent infections at 60 months
(UPN 1) and 55 months (UPN 2) post CBSCT. Clinical data
regarding CBSCT are shown in Table 1. The elevated total
eosinophil counts and serum IgE levels have been normalized
since 7 months post-transplantation in both children (Table
2). Other immunologic parameters including IgG, IgA, IgM,
IgD and lymphocyte subsets are summarized at Table 2. 
To determine whether the genotype was corrected by CB-
SCT, we analyzed the WASP gene sequence before and after
CBSCT in UPN 1. UPN 1 had a single base substitution
(C665T) in exon 7 that results in an amino acid change in
codon 211 (Arg211stop) before CBSCT. Following CBSCT,
UPN1 had a normal sequence at the mutation site in exon
7 of the WASP gene (Fig. 1). 
DISCUSSION
The gene responsible for WAS (WASP) consists of 12 exons
with 1,823 bp. WASP encodes a 502 amino acid protein that
is expressed selectively in hematopoietic stem cell-derived
lineages (4). To date, approximately 100 mutations in the
WASP gene have been described. These mutations consist
of frameshift mutations, missense mutations, or splice-site
mutations, which all give rise to aberrant transcription (4-9).
A correlation between clinical phenotype and genotype was
reported independently by several investigators (7, 9). Imai
et al. (10) observed that patients with missense mutations
were WASP-positive, but patients with nonsense mutations,
large deletions, small deletions, and small insertions were
WASP-negative. Patients with splice anomalies were either
WASP-positive or WASP-negative. Lack of WASP expression
was associated with susceptibility to bacterial, viral, fungal,
and Pneumocystis jiroveci infections and with severe eczema, in-
testinal hemorrhage, death from intracranial bleeding, and
malignancies. They also revealed that the rates for overall sur-
vival and event-free survival were significantly lower in WASP-
negative patients. Conclusively, they recommended HSCT
to improve prognosis, especially for WASP-negative patients.
Recently, HSCT has been the principal modality for cor-
rection of immune deficiencies such as WAS. Since CB has
been successfully transplanted to reconstitute patients with
WAS, as first reported in 1994 (11-16), CB appears to be an
alternative donor source compared with matched unrelated
bone marrow with successful engraftment associated with no
to mild acute GVHD and without development of chronic
GVHD. In this study, we identified 2 WAS patients who had
nonsense mutations in WASP and we successfully treated
them by unrelated CBSCT with engraftment with no asso-
ciated GVHD.
In CBSCT, the immunologic reconstitution resulted in con-
sistent and stable T-cell, B-cell, and natural killer-cell devel-
opment. The kinetics of recovery of phenotypic expression
and function of the T cells occurred between 60 and 100 days
and that of natural killer cells at approximately 180 days (19).
The immunologic parameters, especially CD8 of our patients
also demonstrated normal values after CBSCT.
Furthermore, following CBSCT, we found that UPN1 had
a normal sequence at the mutation site in the exon 7 of WASP
gene. While CBSCT has been successfully performed for phe-
notypic correction including clinical features and immuno-
logical parameters in WAS, our study emphasizes the eviden-
ce of genetic correction as well as phenotypic correction by
CBSCT in WAS. To our knowledge, this is the first report
documenting a genetic correction by CBSCT in WAS. 
Collectively, our data demonstrate that CBs could be an
important source of stem cells for the phenotypic as well as
genotypic correction of genetic diseases such as WAS. 
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